GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArcticZymes Technologies ASA (FRA:B4V) » Definitions » Total Liabilities

ArcticZymes Technologies ASA (FRA:B4V) Total Liabilities : €1.95 Mil (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is ArcticZymes Technologies ASA Total Liabilities?

ArcticZymes Technologies ASA's Total Liabilities for the quarter that ended in Sep. 2024 was €1.95 Mil.

ArcticZymes Technologies ASA's quarterly Total Liabilities declined from Mar. 2024 (€2.53 Mil) to Jun. 2024 (€1.88 Mil) but then increased from Jun. 2024 (€1.88 Mil) to Sep. 2024 (€1.95 Mil).

ArcticZymes Technologies ASA's annual Total Liabilities declined from Dec. 2021 (€3.87 Mil) to Dec. 2022 (€3.28 Mil) and declined from Dec. 2022 (€3.28 Mil) to Dec. 2023 (€2.61 Mil).


ArcticZymes Technologies ASA Total Liabilities Historical Data

The historical data trend for ArcticZymes Technologies ASA's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArcticZymes Technologies ASA Total Liabilities Chart

ArcticZymes Technologies ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.11 2.42 3.87 3.28 2.61

ArcticZymes Technologies ASA Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.56 2.61 2.53 1.88 1.95

ArcticZymes Technologies ASA Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ArcticZymes Technologies ASA's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.878+(0.731+0.001
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=2.61

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=29.495-26.885
=2.61

ArcticZymes Technologies ASA's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.503+(0.442+1.6653345369377E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1.95

Total Liabilities=Total Assets (Q: Sep. 2024 )-Total Equity (Q: Sep. 2024 )
=28.987-27.042
=1.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ArcticZymes Technologies ASA Total Liabilities Related Terms

Thank you for viewing the detailed overview of ArcticZymes Technologies ASA's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


ArcticZymes Technologies ASA Business Description

Traded in Other Exchanges
Address
Sykehusveien 23, Tromso, NOR, 9294
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Germany, Italy, France, and other countries.

ArcticZymes Technologies ASA Headlines

No Headlines